Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 4-4 (IGHV4-4) is a gene segment that encodes the variable region of immunoglobulin heavy chains, which are components of antibodies. This region is essential for the adaptive immune response, enabling the production of a diverse antibody repertoire through genetic recombination. Gene segments like IGHV4-4 are not stand-alone functional proteins, but rather building blocks that, after recombination with other immunoglobulin segments, contribute to antigen specificity in mature B cells and antibodies. As such, IGHV4-4 itself is not considered a classic therapeutic target, receptor, or enzyme, and has no known direct drug interactions or disease associations unless it is involved in abnormal immune restructuring, such as in certain lymphoid malignancies[5][6].\n\n**Justification & Explanation:**\n- **ENSG00000278263** (per databases such as Human Protein Atlas) corresponds to a "novel protein, identical to IGHV4-4" and maps to an immunoglobulin variable region[5][6].\n- This sequence is not a complete gene or protein, but a segment used for *antigen recognition diversity* in antibodies.\n- It does not function as a druggable receptor/enzyme/transcription factor, etc., nor is it typically considered a biomarker or safety concern on its own.\n- Targeting IGHV gene segments therapeutically is uncommon; their primary biological relevance is in immune system diversity.\n- Any "novel protein identical to IGHV4-4" label most likely refers to a variant, pseudogene, or redundant sequence.\n- It is **not a canonical drug target**, and the entry may reflect a data artifact or an under-characterized genomic region.\n\nIf you need structured annotations or databases for immunoglobulin genes, consulting immunogenetics resources such as IMGT will provide further confirmation of the gene’s exact sequence and biological role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 4-4 (IGHV4-4).